BioGaia AB (BIOGY)
11.50
0.00 (0.00%)
USD |
OTCM |
Jul 02, 16:00
BioGaia Revenue (Quarterly): 35.65M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 35.65M |
| December 31, 2023 | 28.04M |
| September 30, 2023 | 29.45M |
| June 30, 2023 | 30.00M |
| March 31, 2023 | 35.10M |
| December 31, 2022 | 25.68M |
| September 30, 2022 | 24.58M |
| June 30, 2022 | 29.44M |
| March 31, 2022 | 30.47M |
| December 31, 2021 | 23.34M |
| September 30, 2021 | 20.13M |
| June 30, 2021 | 24.17M |
| March 31, 2021 | 24.12M |
| December 31, 2020 | 21.82M |
| September 30, 2020 | 14.91M |
| June 30, 2020 | 25.31M |
| March 31, 2020 | 19.01M |
| December 31, 2019 | 21.62M |
| September 30, 2019 | 17.44M |
| June 30, 2019 | 23.54M |
| March 31, 2019 | 18.69M |
| December 31, 2018 | 23.18M |
| September 30, 2018 | 19.53M |
| June 30, 2018 | 23.21M |
| March 31, 2018 | 19.33M |
| Date | Value |
|---|---|
| December 31, 2017 | 20.45M |
| September 30, 2017 | 18.17M |
| June 30, 2017 | 17.72M |
| March 31, 2017 | 15.81M |
| December 31, 2016 | 15.35M |
| September 30, 2016 | 14.80M |
| June 30, 2016 | 16.57M |
| March 31, 2016 | 15.84M |
| December 31, 2015 | 12.28M |
| September 30, 2015 | 12.49M |
| June 30, 2015 | 15.91M |
| March 31, 2015 | 16.70M |
| December 31, 2014 | 16.34M |
| September 30, 2014 | 11.44M |
| June 30, 2014 | 14.00M |
| March 31, 2014 | 29.20M |
| December 31, 2013 | 13.86M |
| September 30, 2013 | 9.504M |
| June 30, 2013 | 13.02M |
| March 31, 2013 | 12.15M |
| December 31, 2012 | 10.89M |
| September 30, 2012 | 9.316M |
| June 30, 2012 | 10.92M |
| March 31, 2012 | 64.36M |
| December 31, 2011 | 12.22M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
14.91M
Minimum
Sep 2020
35.65M
Maximum
Mar 2024
25.28M
Average
24.58M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | 0.0454M |
| Calliditas Therapeutics AB | 28.49M |
| Oncopeptides AB | 0.26M |
| Olink Holding AB | 28.75M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 11.75M |
| Total Expenses (Quarterly) | 21.85M |
| EPS Diluted (Quarterly) | 0.1167 |
| Enterprise Value | 1.012B |
| Gross Profit Margin (Quarterly) | 71.89% |
| Profit Margin (Quarterly) | 32.95% |
| Earnings Yield | 3.04% |
| Operating Earnings Yield | 3.56% |
| Normalized Earnings Yield | 3.040 |